Answers are grounded in this paper and cite their sources.
GII.4 variants cause the highest burden of norovirus acute gastroenteritis (AGE) in children aged <2 years. In a phase 2b trial (NCT05281094), infants 5 months of age received two doses of a GI.1/GII.4c virus-like particle vaccine candidate (N=1425) or placebo (N=1399). Over 6-months, 23 vaccine and 29 placebo recipients experienced GII.4 moderate/severe AGE resulting in a vaccine efficacy of 13% (95% CI: -53%, 50%; mFAS). Lack of protection coincided with narrow surrogate neutralizing antibody titer (sNAbT) breadth post-vaccination. Post-GII.4 AGE of any severity, sNAbT to heterotypic GII.4 variants was higher in vaccinees compared to placebo recipients at ~13 months of age, indicating multiple variant exposures improved sNAbT breadth. Phase 2 trial data from children and adults suggest that GII.4 pre-existing immunity may be a pre-requisite for developing broad GII.4 sNAbT necessary for protection. Consequently, future infant norovirus vaccines should strategically prioritize enhancement of sNAb titer and breadth in naïve populations.
No takes yet. Share an insight, caveat, or question.
Lindesmith et al. (2026) studied this question.